PVLANasdaqPharmaceutical PreparationsFiscal year ends December 31
PALVELLA THERAPEUTICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$122.96+2.66 (+2.21%)
Close on Oct 19, 2026
- Market cap
- $1.77B
- P/E (TTM)
- –
- Dividend yield
- –
PALVELLA THERAPEUTICS, INC. revenue by segment
By business segment
By product or service
| Revenue | TTM Q3 20 | TTM Q2 20 | TTM Q1 20 | TTM Q4 19 | % of revenue |
|---|---|---|---|---|---|
| Customer revenue | $38.92M | $39.93M | $33.72M | $32.07M | 87.0% |
| Collaboration revenue | $5.80M | $16.98M | $17.27M | $14.21M | 13.0% |
By region
From the segment and revenue-disaggregation notes of Palvella Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.